Uses of DNA methylation in cancer diagnosis and risk assessment

Carmen Jerónimo, Rui Henrique, David Sidransky

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Over the last decade, molecular markers have emerged as promising tools for early cancer detection, patient management, and assessment of prognosis. Research into nucleic acid-based markers has blossomed as their ability to allow for robust analysis of clinical samples (tissue or body fluids) in a high-throughput fashion [1] has become recognized. Among the DNA-based approaches, DNA methylation offers several advantages over other types of molecular markers. Promoter hypermethylation of key regulatory genes in human cancers is a frequent event and is often associated with transcription silencing [2]. In addition, most of the common human tumors appear to have one or more hypermethylated loci when several methylation markers are examined together [3]. Furthermore, a specific pattern of hypermethylation for each type of human cancer is emerging from the rapidly growing list of cancer-related methylated genes, eventually permitting the identification of the tissue of origin of a particular neoplasm [3]. Notably, promoter methylation occurs early in tumorigenesis and may be identified even in preneoplastic lesions [4-6]. From a methodological standpoint, the identification of methylated DNA is easier than RNA manipulation followed by reverse transcription-PCR, since DNA harboring methylation is more stable. Likewise, detection of methylated DNA is particularly suited for clinical samples because methylation is a positive signal that is less likely to be masked through contaminant normal DNA. Thus, methylation markers provide sensitive detection in samples where tumor DNA is scarce or diluted by excess normal DNA.

Original languageEnglish (US)
Title of host publicationDNA Methylation
Subtitle of host publicationApproaches, Methods, and Applications
PublisherCRC Press
Pages11-26
Number of pages16
ISBN (Electronic)9780203487013
ISBN (Print)9780849320507
DOIs
StatePublished - Jan 1 2004

Fingerprint

DNA Methylation
Risk assessment
Methylation
DNA
Neoplasms
Transcription
Tumors
Genes
Tissue
Body fluids
Body Fluids
Regulator Genes
Early Detection of Cancer
Nucleic Acids
Reverse Transcription
Carcinogenesis
Throughput
RNA
Impurities
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Jerónimo, C., Henrique, R., & Sidransky, D. (2004). Uses of DNA methylation in cancer diagnosis and risk assessment. In DNA Methylation: Approaches, Methods, and Applications (pp. 11-26). CRC Press. https://doi.org/10.1201/9780203487013

Uses of DNA methylation in cancer diagnosis and risk assessment. / Jerónimo, Carmen; Henrique, Rui; Sidransky, David.

DNA Methylation: Approaches, Methods, and Applications. CRC Press, 2004. p. 11-26.

Research output: Chapter in Book/Report/Conference proceedingChapter

Jerónimo, C, Henrique, R & Sidransky, D 2004, Uses of DNA methylation in cancer diagnosis and risk assessment. in DNA Methylation: Approaches, Methods, and Applications. CRC Press, pp. 11-26. https://doi.org/10.1201/9780203487013
Jerónimo C, Henrique R, Sidransky D. Uses of DNA methylation in cancer diagnosis and risk assessment. In DNA Methylation: Approaches, Methods, and Applications. CRC Press. 2004. p. 11-26 https://doi.org/10.1201/9780203487013
Jerónimo, Carmen ; Henrique, Rui ; Sidransky, David. / Uses of DNA methylation in cancer diagnosis and risk assessment. DNA Methylation: Approaches, Methods, and Applications. CRC Press, 2004. pp. 11-26
@inbook{a70aeeef661e45a6a68a89f9198259b0,
title = "Uses of DNA methylation in cancer diagnosis and risk assessment",
abstract = "Over the last decade, molecular markers have emerged as promising tools for early cancer detection, patient management, and assessment of prognosis. Research into nucleic acid-based markers has blossomed as their ability to allow for robust analysis of clinical samples (tissue or body fluids) in a high-throughput fashion [1] has become recognized. Among the DNA-based approaches, DNA methylation offers several advantages over other types of molecular markers. Promoter hypermethylation of key regulatory genes in human cancers is a frequent event and is often associated with transcription silencing [2]. In addition, most of the common human tumors appear to have one or more hypermethylated loci when several methylation markers are examined together [3]. Furthermore, a specific pattern of hypermethylation for each type of human cancer is emerging from the rapidly growing list of cancer-related methylated genes, eventually permitting the identification of the tissue of origin of a particular neoplasm [3]. Notably, promoter methylation occurs early in tumorigenesis and may be identified even in preneoplastic lesions [4-6]. From a methodological standpoint, the identification of methylated DNA is easier than RNA manipulation followed by reverse transcription-PCR, since DNA harboring methylation is more stable. Likewise, detection of methylated DNA is particularly suited for clinical samples because methylation is a positive signal that is less likely to be masked through contaminant normal DNA. Thus, methylation markers provide sensitive detection in samples where tumor DNA is scarce or diluted by excess normal DNA.",
author = "Carmen Jer{\'o}nimo and Rui Henrique and David Sidransky",
year = "2004",
month = "1",
day = "1",
doi = "10.1201/9780203487013",
language = "English (US)",
isbn = "9780849320507",
pages = "11--26",
booktitle = "DNA Methylation",
publisher = "CRC Press",
address = "United States",

}

TY - CHAP

T1 - Uses of DNA methylation in cancer diagnosis and risk assessment

AU - Jerónimo, Carmen

AU - Henrique, Rui

AU - Sidransky, David

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Over the last decade, molecular markers have emerged as promising tools for early cancer detection, patient management, and assessment of prognosis. Research into nucleic acid-based markers has blossomed as their ability to allow for robust analysis of clinical samples (tissue or body fluids) in a high-throughput fashion [1] has become recognized. Among the DNA-based approaches, DNA methylation offers several advantages over other types of molecular markers. Promoter hypermethylation of key regulatory genes in human cancers is a frequent event and is often associated with transcription silencing [2]. In addition, most of the common human tumors appear to have one or more hypermethylated loci when several methylation markers are examined together [3]. Furthermore, a specific pattern of hypermethylation for each type of human cancer is emerging from the rapidly growing list of cancer-related methylated genes, eventually permitting the identification of the tissue of origin of a particular neoplasm [3]. Notably, promoter methylation occurs early in tumorigenesis and may be identified even in preneoplastic lesions [4-6]. From a methodological standpoint, the identification of methylated DNA is easier than RNA manipulation followed by reverse transcription-PCR, since DNA harboring methylation is more stable. Likewise, detection of methylated DNA is particularly suited for clinical samples because methylation is a positive signal that is less likely to be masked through contaminant normal DNA. Thus, methylation markers provide sensitive detection in samples where tumor DNA is scarce or diluted by excess normal DNA.

AB - Over the last decade, molecular markers have emerged as promising tools for early cancer detection, patient management, and assessment of prognosis. Research into nucleic acid-based markers has blossomed as their ability to allow for robust analysis of clinical samples (tissue or body fluids) in a high-throughput fashion [1] has become recognized. Among the DNA-based approaches, DNA methylation offers several advantages over other types of molecular markers. Promoter hypermethylation of key regulatory genes in human cancers is a frequent event and is often associated with transcription silencing [2]. In addition, most of the common human tumors appear to have one or more hypermethylated loci when several methylation markers are examined together [3]. Furthermore, a specific pattern of hypermethylation for each type of human cancer is emerging from the rapidly growing list of cancer-related methylated genes, eventually permitting the identification of the tissue of origin of a particular neoplasm [3]. Notably, promoter methylation occurs early in tumorigenesis and may be identified even in preneoplastic lesions [4-6]. From a methodological standpoint, the identification of methylated DNA is easier than RNA manipulation followed by reverse transcription-PCR, since DNA harboring methylation is more stable. Likewise, detection of methylated DNA is particularly suited for clinical samples because methylation is a positive signal that is less likely to be masked through contaminant normal DNA. Thus, methylation markers provide sensitive detection in samples where tumor DNA is scarce or diluted by excess normal DNA.

UR - http://www.scopus.com/inward/record.url?scp=35948931202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35948931202&partnerID=8YFLogxK

U2 - 10.1201/9780203487013

DO - 10.1201/9780203487013

M3 - Chapter

AN - SCOPUS:35948931202

SN - 9780849320507

SP - 11

EP - 26

BT - DNA Methylation

PB - CRC Press

ER -